Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Eu­ro­pean Com­mis­sion grants EU Mar­ket­ing Au­tho­ri­sa­tions for SARS-CoV-2 Neu­tral­is­ing Mon­o­clon­al An­ti­bod­ies Ron­apreve (casiriv­imab/imde­vimab) and Regkirona (reg­dan­vimab)

On 12 November 2021, the European Commission granted marketing authorisations for the monoclonal antibodies Ronapreve (casirivimab/imdevimab) from Roche Registration GmbH and Regkirona (regdanvimab) from Celltrion Healthcare Hungary Kft.

The authorisations followed the recommendations of the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) on 11 November 2021.

Ronapreve and Regkirona are among the SARS-CoV-2 neutralising antibodies. They are the first monoclonal antibodies for COVID-19 therapy to receive marketing authorisation from the European Commission.

EU flags in front of the European Commission building in Brussels (Source: NakNakNak/Pixabay.com)

Updated: 15.11.2021